NCT05199337 - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions

AmyloidosisAL Amyloidosis

Interventions

DRUG

ZN-d5

ZN-d5 will be administered orally

Trial Locations (21)

2145

Blackwater (Westmead) Hospital, Westmead

4102

Princess Alexandra Hospital, Brisbane

5000

Royal Adelaide Hospital, Adelaide

30120

Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar

37203

Tennessee Oncology, Nashville

63130

Washington University, St Louis

70112

Tulane University, New Orleans

80218

Colorado Blood Cancer Institute, Denver

90089

University of Southern California, Los Angeles

3109601

Rambam Hospital, Haifa

Unknown

Sir Charles Gairdner Hospital, Nedlands

Bank of Cyprus Hospital, Nicosia

Hadassah Medical Center, Jerusalem

Sheba Medical Center, Tel Aviv

Tel Aviv Sourasky Medical Center PPDS, Tel Aviv

IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola Malpighi, Bologna

Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

ICO Badalona-H.U. Germans Trias i Pujol, Barcelona

Clinico de Salamanca, Salamanca

115 28

National and Kapodistrian University of Athens, Athens

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors

lead

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

INDUSTRY